eligibility_summary
Eligible: adults 18–65 with ovarian/NSCLC/breast/gastric cancer and symptomatic serous effusions post standard tx, ECOG 0–2, life ≥3 mo, adequate counts, renal/hepatic (CrCl ≥60, ALT/AST ≤2.5×ULN, bili ≤1.5×), cardiac (LVEF ≥50%), off chemo/targeted ≥3 wks, contraception. Exclude: prior CAR‑T, infection/GVHD/other cancer, active HBV/HCV/HIV, major uncontrolled disease (cardio/cerebrovascular, HTN, psych), long‑term post‑transplant immunosuppression, recent ≤6 mo VTE/PE, pregnancy/lactation, PI decision.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Dual-targeting VEGFR1/PD‑L1 CAR‑T cells (gene‑modified T‑cell immunotherapy) delivered regionally into the pleural or peritoneal cavity. Mechanism: Engineered T cells express a chimeric antigen receptor recognizing VEGFR1 and PD‑L1, antigen engagement activates T‑cell cytotoxicity, aiming to kill VEGFR1+ and/or PD‑L1+ cells, disrupt VEGF/VEGFR1‑driven angiogenesis, and overcome PD‑L1–mediated immune suppression. Targets/cell types: VEGFR1 on tumor vasculature/endothelial cells and some tumor/myeloid cells, PD‑L1 on tumor cells and immunosuppressive stromal/immune cells within pleural/peritoneal metastases. Population: refractory ovarian, breast, lung, gastric cancers with malignant effusions/ascites. Study: Phase Ia/Ib, single‑arm, 3+3 dose escalation with expansion, endpoints emphasize safety (CTCAE v5.0) and antitumor activity (RECIST 1.1).